DECHRA PHARMACEUTICALS LIMITED | Sales 2022 | 682M 885M 1.21B | Sales 2023 | 762M 988M 1.35B | Capitalization | 4.2B 5.45B 7.45B |
|---|---|---|---|---|---|
| Net income 2022 | 58M 75.26M 103M | Net income 2023 | -27M -35.03M -47.9M | EV / Sales 2022 | 5.8 x |
| Net Debt 2022 | 208M 270M 369M | Net Debt 2023 | 430M 558M 763M | EV / Sales 2023 | 6.08 x |
| P/E ratio 2022 |
64.8
x | P/E ratio 2023 |
-150
x | Employees | - |
| Yield 2022 |
1.3% | Yield 2023 |
0.34% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Page
CEO | Chief Executive Officer | 63 | 97-06-12 |
Paul Sandland
DFI | Director of Finance/CFO | 44 | 09-12-31 |
Jamie Adams
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Page
CEO | Chief Executive Officer | 63 | 97-06-12 |
Alison Platt
CHM | Chairman | - | 20-02-29 |
John Shipsey
BRD | Director/Board Member | - | 22-05-31 |
Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows:
- companion animal products (74.6%);
- food producing animal products (11.5%);
- equine health products (7.3%);
- animal feeds (5.1%);
- other (1.5%): products manufactured by third parties.
Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).
Sector
-
